These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21484283)

  • 21. A randomized crossover study to compare efavirenz and etravirine treatment.
    Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
    AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz and the CNS: what we already know and questions that need to be answered.
    Apostolova N; Funes HA; Blas-Garcia A; Galindo MJ; Alvarez A; Esplugues JV
    J Antimicrob Chemother; 2015 Oct; 70(10):2693-708. PubMed ID: 26203180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychiatric effects of efavirenz: delayed onset.
    Dawson S; Woods C
    Int J STD AIDS; 2005 Nov; 16(11):769-70. PubMed ID: 16303077
    [No Abstract]   [Full Text] [Related]  

  • 24. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
    Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
    Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.
    Seden K; Kiiza D; Laker E; Arinaitwe WJ; Waitt C; Lamorde M; Khoo S
    J Antimicrob Chemother; 2018 Nov; 73(11):3158-3161. PubMed ID: 30085168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
    van Luin M; Bannister WP; Mocroft A; Reiss P; Di Perri G; Peytavin G; Molto J; Karlson A; Castagna A; Beniowski M; Lundgren JD; Burger DM;
    Antivir Ther; 2009; 14(1):75-83. PubMed ID: 19320239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
    Lochet P; Peyrière H; Lotthé A; Mauboussin JM; Delmas B; Reynes J
    HIV Med; 2003 Jan; 4(1):62-6. PubMed ID: 12534961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efavirenz as a cause of ataxia in children.
    Hauptfleisch MP; Moore DP; Rodda JL
    S Afr Med J; 2015 Nov; 105(11):897-8. PubMed ID: 26632310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
    Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
    J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.
    Gallego L; Barreiro P; del Río R; González de Requena D; Rodríguez-Albariño A; González-Lahoz J; Soriano V
    Clin Infect Dis; 2004 Feb; 38(3):430-2. PubMed ID: 14727217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition modeling of neuropsychiatric impairment in HIV.
    Bisaso KR; Mukonzo JK; Ette EI
    Comput Biol Med; 2016 Jun; 73():141-6. PubMed ID: 27107677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.